Adagio Therapeutics Inc.

04/06/2022 | Press release | Distributed by Public on 04/06/2022 15:03

Amendment to Initial Statement of Beneficial Ownership (Form 3/A)

Ownership Submission
FORM 3/A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Cox Christopher T
2. Date of Event Requiring Statement (Month/Day/Year)
2022-03-28
3. Issuer Name and Ticker or Trading Symbol
Adagio Therapeutics, Inc. [ADGI]
(Last) (First) (Middle)
C/O POPULATION HEALTH PARTNERS, L.P. , 1200 MORRIS TURNPIKE, SUITE 3005
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
/ See Explanation of Responses
5. If Amendment, Date Original Filed(Month/Day/Year)
2022-03-30
(Street)
SHORT HILLS NJ 07078
6. Individual or Join/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security 2. Amount of Securities Beneficially Owned 3. Ownership Form: Direct (D) or Indirect (I) 4. Nature of Indirect Beneficial Ownership
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Date Exercisable and Expiration Date 3. Title and Amount of Securities Underlying Derivative Security 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 6. Nature of Indirect Beneficial Ownership
Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Cox Christopher T
C/O POPULATION HEALTH PARTNERS, L.P.
1200 MORRIS TURNPIKE, SUITE 3005
SHORT HILLS, NJ07078



See Explanation of Responses
Population Health Equity Partners VII, L.P.
C/O POPULATION HEALTH PARTNERS, L.P.
1200 MORRIS TURNPIKE SUITE 3005
SHORT HILLS, NJ07078



See Explanation of Responses
Population Health Equity Partners III GP, LLC
C/O POPULATION HEALTH PARTNERS, L.P.
1200 MORRIS TURNPIKE, SUITE 3005
SHORT HILLS, NJ07078



See Explanation of Responses
Population Health Equity Partners III, L.P.
C/O POPULATION HEALTH PARTNERS, L.P.
1200 MORRIS TURNPIKE, SUITE 3005
SHORT HILLS, NJ07078



See Explanation of Responses
Population Health Equity Partners VII GP, LLC
C/O POPULATION HEALTH PARTNERS, L.P.
1200 MORRIS TURNPIKE, SUITE 3005
SHORT HILLS, NJ07078



See Explanation of Responses

Signatures

/s/ Christopher Cox 2022-04-06
**Signature of Reporting Person Date
/s/ Christopher Cox, Managing Member, Population Health Equity Partners III GP, LLC, General Partner of Population Health Equity Partners III, L.P. 2022-04-06
**Signature of Reporting Person Date
/s/ Christopher Cox, Managing Member, Population Health Equity Partners III GP, LLC 2022-04-06
**Signature of Reporting Person Date
/s/ Christopher Cox, Managing Member, Population Health Equity Partners VII GP, LLC, General Partner of Population Health Equity Partners VII, L.P. 2022-04-06
**Signature of Reporting Person Date
/s/ Christopher Cox, Managing Member, Population Health Equity Partners VII GP, LLC 2022-04-06
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 3 is not being filed in connection with the acquisition or disposition of any securities of the Issuer.
(2) 359,662 shares of Common Stock are held directly by Population Health Equity Partners III, L.P. ("PH III") and a further 320,160 shares of Common Stock are held directly by Population Health Equity Partners VII, L.P. ("PH VII"). PH III is controlled by Population Health Equity Partners III GP, LLC ("PH III GP"), its general partner, and PH VII is controlled by Population Health Equity Partners VII GP, LLC ("PH VII GP"), its general partner. Clive Meanwell and Christopher Cox are the sole managing members of both PH III GP and PH VII GP and may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held directly by PH III and PH VII. Clive Meanwell and Christopher Cox disclaim beneficial ownership of the shares held directly by PH III and PH VII, except to the extent of their pecuniary interests therein, if any. Clive Meanwell has filed a separate Form 3 in respect of the Issuer.
(3) On March 28, 2022, PH III, PH VII and Clive Meanwell ("PH") and (i) Mithril II LP ("Mithril"), (ii) M28 Capital Management LP (together with certain of its affiliates, "M28"), (iii) Polaris Venture Partners V, L.P. and certain affiliates (collectively, "Polaris") and (iv) Adimab, LLC, orally agreed to coordinate and cooperate in certain of their activities with regard to the Issuer, which agreement was subsequently memorialized, also on March 28, 2022, in an email circulated among representatives of such persons. That agreement provides that each such person will vote its shares of Common Stock in favor of the election of certain director nominees at the Issuer's 2022 annual meeting. By virtue of such agreement, the forgoing persons may be deemed to be part of a "group" (within the meaning of Section 13(d)(3) of the Exchange Act) comprised of such persons.
(4) The Reporting Persons expressly disclaim beneficial ownership over any Common Stock that they may be deemed to beneficially own solely by reason of the agreement reached among Population Health, Mithril, M28, Polaris and Adimab, LLC, and beneficial ownership of any securities of the Issuer other than those reported on this Form 3 in which they have a direct pecuniary interest. This filing shall not be deemed an admission that the Reporting Persons are 10% shareholders for purposes of Section 16 of the Exchange Act.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.